Researchers at the University of California, Davis have developed advanced compounds targeting neuraminidase activity to combat viral infections and understand cellular mechanisms.
This technology encompasses the synthesis of sialic acid (Sia) derivatives designed for the inhibition of neuraminidases, crucial in the pathogenesis of viral infections and several cellular processes. These compounds, including pharmaceutically acceptable salts, are based on specific structural formulas that allow for targeted interaction with neuraminidases, offering potential therapeutic and research applications.
Patent Pending
infectious disease, Influenza A, influenza virus, influenza virus neuraminidase, influenza virus neuraminidase substrate, inhibitors & probes, influenza virus vaccine